Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

Novel MS Drug Good as Gold in Phase II Study

Medpagetoday

April 25, 2023

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH

NeurologyLive

April 25, 2023

ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein

Biopharma Dive

March 27, 2023

CNM-Au8 found to delay clinical worsening in ALS HEALEY trial

ALS News Today

March 10, 2023

ALS Advances and Hot Topics for MDA 2023: Matthew B. Harms, MD

NeurologyLive

March 9, 2023

CNM-Au8 Demonstrates Significant Survival Benefit in HEALEY-ALS Interim Analysis

NeurologyLive

March 9, 2023

Clene's Nanocrystal ALS treatment bounces back with positive data

BioSpace

March 9, 2023

MS New Notes: Briumvi, vitamin D, CNM-Au8

Multiple Sclerosis News Today

March 6, 2023

ACTRIMS 2023 – Michael Hotchkin, Chief Development Officer, Clene Inc.

Multiple Sclerosis News Today

February 27, 2023

CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter

NeurologyLive

February 14, 2023

Pagination

Current page 1
Page 2
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved